Previous Page  9 / 32 Next Page
Information
Show Menu
Previous Page 9 / 32 Next Page
Page Background

At this interim analysis of OS (data maturity, 25%), the OS benefit did not reach formal statistical significance for osimertinib

1 … 4 5 6 7 8 9 10 11 12 13 14 15 … 32